Today's post from sciencedaily.com (see link below) may at first sight seem a little difficult to understand but basically, when the body experiences pain, there are pain receptors on the surface of nerve cells that identify it and transmit the information further and let you feel that pain. If the pain is extreme, sometimes these pain receptors retreat to the nucleus of the cell, as if it's 'safer' there. Pain relieving drugs are designed to block the pain signals in the receptors at the surface of the cell but if the receptors have migrated to the nucleus then the drugs don't have any effect. This knowledge enables researchers to design pain-relieving drugs that can penetrate the nerve cell to the nucleus and thus block the signals from reaching the receptors. They can then 'safely' return to the surface of the cell. At least that's the theory and although it may seem like double-dutch to most of us, sometimes it's interesting to know in which direction the scientists are going.

Location may be key to effectively controlling pain Date:February 3, 2016 Source:McGill University
In real estate, location is key. It now seems the same concept holds true when it comes to stopping pain. New research published in Nature Communications indicates that the location of receptors that transmit pain signals is important in how big or small a pain signal will be -- and therefore how effectively drugs can block those signals.
Blocking pain receptors in the nucleus of spinal nerve cells could more effectively control pain than interfering with the same type of receptors located on cell surfaces. The scientists also found that when spinal nerve cells encounter a painful stimulus, some of the receptors will migrate from the cell surface into the nucleus.
A team of researchers led by McGill University's Director of Anesthesia Research Terence Coderre and Karen O'Malley at Washington University in St. Louis, found that rats treated with investigational drugs to block the activity of the receptors in the nucleus soon began behaving in ways that led them to believe the animals had gotten relief from neuropathic pain. According to Prof. Coderre, "drugs that penetrate the spinal nerve cells to block receptors at the nucleus were effective at relieving pain, while those that don't penetrate the nerve cells were not. Rats with nerve injuries had less spontaneous pain and less pain hypersensitivity after blocking receptors at the nucleus, while the pain sensitivity of normal rats was not affected."
Location is key
Scientists have been studying glutamate receptors in the pain pathway for decades. What's new, Coderre explained, is that these most recent experiments -- in cell cultures and rats -- demonstrate that the location of the receptor in the cell has a major effect on the cell's ability to transmit pain signals.
The researchers focused mainly on nerve cells in the spinal cord, an important area for transmitting pain signals coming from all parts of the body.
"We'll now focus our research at determining what events cause the glutamate receptors to migrate to the nucleus, and how to produce drugs that more specifically block glutamate receptors only at the nucleus," added Coderre.
Story Source:
The above post is reprinted from materials provided by McGill University. The original item was written by Cynthia Lee. Note: Materials may be edited for content and length.
Journal Reference:
Kathleen Vincent, Virginia M. Cornea, Yuh-Jiin I. Jong, André Laferrière, Naresh Kumar, Aiste Mickeviciute, Jollee S. T. Fung, Pouya Bandegi, Alfredo Ribeiro-da-Silva, Karen L. O’Malley, Terence J. Coderre. Intracellular mGluR5 plays a critical role in neuropathic pain. Nature Communications, 2016; 7: 10604 DOI: 10.1038/NCOMMS10604
http://www.sciencedaily.com/releases/2016/02/160203111018.htm
Today's post from medicalxpress.com (see link below) looks at the potential melatonin has for relieving neuropathic pain. You've probably heard of melatonin in relation to sleep problems but previous research has shown that over-the-counter melatonin has no effect on nerve pain problems. Now scientists have found that UCM924, a melatonin MT2 receptor drug, relieves chronic pain in animal models because it is directed at the right pain receptors in the brain. In this way, it can turn off the neurons responsible for sending pain signals. An interesting development that may bear fruit in the future.
Study shows potential new therapy for neuropathic pain
Provided by McGill University February 18, 2015
An international study led by scientists at McGill University reports, for the first time, that drugs that selectively target the melatonin MT2 receptor represent a novel class of analgesic drugs that could be used to treat patients with neuropathic pain.
Neuropathic pain is a disorder characterized by severe pain that sometimes develops following nerve damage resulting from conditions such as shingles, injury, amputation, autoimmune inflammation and cancer. It is a permanent pain that persists for months or years.
An estimated 7% to 8% of adults worldwide suffer from neuropathic pain, with 5% of cases considered severe. The problem has significant economic implications, including reduced productivity and substantial health care costs.
Melatonin, a neurohormone present in mammals, acts on the brain by activating two receptors called "MT1" and "MT2" that are responsible for regulating several functions including sleep, depression, anxiety and circadian rhythms.
Now, a team led by Dr. Gabriella Gobbi, Associate Professor in the Department of Psychiatry of McGill's Faculty of Medicine, has demonstrated that UCM924, a melatonin MT2 receptor drug, relieves chronic pain in animal models; the team has also identified the drug's mechanism of action in the brain. UCM924, by activating the MT2 receptors in the periaqueductal grey (a brain area controlling pain), is able to switch off the neurons that trigger pain and switch on the ones that turn off pain. The findings are reported in the February issue of the journal PAIN.
"There are very limited treatments available for neuropathic pain, and a lot of patients use opioids," says Dr. Gobbi, who is also a researcher at the Research Institute of the McGill University Health Centre (RI-MUHC). "In the long term, these can lead to addiction and severe side effects, including dependence and tolerance, opioid-induced hyperalgesia (the pain becomes even worse), and risk of death. For these reasons, identifying novel analgesics is of keen interest in the medical field today."
Previous studies have shown that over-the-counter melatonin has very limited effect. Dr. Gobbi and her team demonstrated that this is because exogenous melatonin activates both MT1 and MT2 receptors, which have conflicting and opposite effects.
In the course of their work to investigate the efficacy of MT2 receptor drugs for insomnia, the researchers discovered that UCM924 also soothes neuropathic pain at lower doses. This suggests that these drugs could offer relief both to people who suffer from pain during the day, using low doses, and from insomnia at night, using higher doses. At least 50-70% of patients with neuropathic pain conditions complain of significant sleep disturbance, and this new study unveils how the mechanisms of pain and sleep are closely related.
The research team is now looking for partners interested in pursuing clinical development and eventual commercialization of these novel drugs.
Explore further: Combining epilepsy drug, morphine can result in less pain, lower opioid doses
More information: "Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways" Martha Lopez-Canul, Enza Palazzo, Sergio Dominguez-Lopez, Livio Luongo, Baptiste Lacoste, Stefano Comai, Debora Angeloni, Franco Fraschini, Serena Boccella, Gilberto Spadoni, Annalida Bedini, Giorgio Tarzia, Sabatino Maione, Vinicio Granados-Soto, Gabriella Gobbi., Pain. 2015 Feb; 156(2):305-17. DOI: 10.1097/01.j.pain.0000460311.71572.5f.
Journal reference: Pain
http://medicalxpress.com/news/2015-02-potential-therapy-neuropathic-pain.html